Literature DB >> 21828122

N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.

Richard W J Groen1, Martin F M de Rooij, Kinga A Kocemba, Rogier M Reijmers, Anneke de Haan-Kramer, Marije B Overdijk, Linda Aalders, Henk Rozemuller, Anton C M Martens, P Leif Bergsagel, Marie José Kersten, Steven T Pals, Marcel Spaargaren.   

Abstract

BACKGROUND: Multiple myeloma is a hematologic malignancy characterized by a clonal expansion of malignant plasma cells in the bone marrow, which is accompanied by the development of osteolytic lesions and/or diffuse osteopenia. The intricate bi-directional interaction with the bone marrow microenvironment plays a critical role in sustaining the growth and survival of myeloma cells during tumor progression. Identification and functional analysis of the (adhesion) molecules involved in this interaction will provide important insights into the pathogenesis of multiple myeloma. DESIGN AND METHODS: Multiple myeloma cell lines and patients' samples were analyzed for expression of the adhesion molecule N-cadherin by immunoblotting, flow cytometry, immunofluorescence microscopy, immunohistochemistry and expression microarray. In addition, by means of blocking antibodies and inducible RNA interference we studied the functional consequence of N-cadherin expression for the myeloma cells, by analysis of adhesion, migration and growth, and for the bone marrow microenvironment, by analysis of osteogenic differentiation.
RESULTS: The malignant plasma cells in approximately half of the multiple myeloma patients, belonging to specific genetic subgroups, aberrantly expressed the homophilic adhesion molecule N-cad-herin. N-cadherin-mediated cell-substrate or homotypic cell-cell adhesion did not contribute to myeloma cell growth in vitro. However, N-cadherin directly mediated the bone marrow localization/retention of myeloma cells in vivo, and facilitated a close interaction between myeloma cells and N-cadherin-positive osteoblasts. Furthermore, this N-cadherin-mediated interaction contributed to the ability of myeloma cells to inhibit osteoblastogenesis.
CONCLUSIONS: Taken together, our data show that myeloma cells frequently display aberrant expression of N-cadherin and that N-cadherin mediates the interaction of myeloma cells with the bone marrow microenvironment, in particular the osteoblasts. This N-cadherin-mediated interaction inhibits osteoblast differentiation and may play an important role in the pathogenesis of myeloma bone disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828122      PMCID: PMC3208683          DOI: 10.3324/haematol.2010.038133

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  46 in total

Review 1.  Cadherin switching.

Authors:  Margaret J Wheelock; Yasushi Shintani; Masato Maeda; Yuri Fukumoto; Keith R Johnson
Journal:  J Cell Sci       Date:  2008-03-15       Impact factor: 5.285

2.  Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum.

Authors:  Henk-Jan Prins; Henk Rozemuller; Simone Vonk-Griffioen; Vivienne G M Verweij; Wouter J A Dhert; Ineke C M Slaper-Cortenbach; Anton C M Martens
Journal:  Tissue Eng Part A       Date:  2009-12       Impact factor: 3.845

3.  Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.

Authors:  W J Chng; W M Kuehl; P L Bergsagel; R Fonseca
Journal:  Leukemia       Date:  2007-09-06       Impact factor: 11.528

Review 4.  Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling.

Authors:  Julian Heuberger; Walter Birchmeier
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

5.  N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation.

Authors:  Eric Haÿ; Emmanuel Laplantine; Valérie Geoffroy; Monique Frain; Thomas Kohler; Ralph Müller; Pierre J Marie
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 4.272

6.  Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.

Authors:  Rogier M Reijmers; Richard W J Groen; Henk Rozemuller; Annemieke Kuil; Anneke de Haan-Kramer; Tamás Csikós; Anton C M Martens; Marcel Spaargaren; Steven T Pals
Journal:  Blood       Date:  2009-11-13       Impact factor: 22.113

Review 7.  Cadherins as novel targets for anti-cancer therapy.

Authors:  Orest W Blaschuk; Emmanuelle Devemy
Journal:  Eur J Pharmacol       Date:  2009-10-16       Impact factor: 4.432

8.  Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.

Authors:  Jui Dutta-Simmons; Yunyu Zhang; Gullu Gorgun; Moshe Gatt; Mala Mani; Teru Hideshima; Kohichi Takada; Nicole E Carlson; Daniel E Carrasco; Yu-Tzu Tai; Noopur Raje; Anthony G Letai; Kenneth C Anderson; Daniel R Carrasco
Journal:  Blood       Date:  2009-08-03       Impact factor: 22.113

Review 9.  Wnt pathway, an essential role in bone regeneration.

Authors:  Yan Chen; Benjamin A Alman
Journal:  J Cell Biochem       Date:  2009-02-15       Impact factor: 4.429

Review 10.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

View more
  14 in total

1.  N-cadherin upregulation mediates adaptive radioresistance in glioblastoma.

Authors:  Satoru Osuka; Dan Zhu; Zhaobin Zhang; Chaoxi Li; Christian T Stackhouse; Oltea Sampetrean; Jeffrey J Olson; G Yancey Gillespie; Hideyuki Saya; Christopher D Willey; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

2.  Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.

Authors:  Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancer Lett       Date:  2020-01-31       Impact factor: 8.679

3.  N-cadherin impedes proliferation of the multiple myeloma cancer stem cells.

Authors:  Nicole M Sadler; Britney R Harris; Brittany A Metzger; Julia Kirshner
Journal:  Am J Blood Res       Date:  2013-12-18

4.  Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche.

Authors:  Wenting Zhang; Yexin Gu; Qiaoling Sun; David S Siegel; Peter Tolias; Zheng Yang; Woo Y Lee; Jenny Zilberberg
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 5.  Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease.

Authors:  Thomas R Cox; Janine T Erler; Robin M H Rumney
Journal:  Calcif Tissue Int       Date:  2017-11-02       Impact factor: 4.333

6.  LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.

Authors:  Krzysztof M Mrozik; Chee M Cheong; Duncan R Hewett; Jacqueline E Noll; Khatora S Opperman; Alaknanda Adwal; Darryl L Russell; Orest W Blaschuk; Kate Vandyke; Andrew C W Zannettino
Journal:  FASEB Bioadv       Date:  2020-06-15

Review 7.  Cadherin Signaling in Cancer: Its Functions and Role as a Therapeutic Target.

Authors:  Weina Yu; Li Yang; Ting Li; Yi Zhang
Journal:  Front Oncol       Date:  2019-10-04       Impact factor: 6.244

Review 8.  Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma.

Authors:  Mara N Zeissig; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

Review 9.  N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer.

Authors:  Krzysztof Marek Mrozik; Orest William Blaschuk; Chee Man Cheong; Andrew Christopher William Zannettino; Kate Vandyke
Journal:  BMC Cancer       Date:  2018-10-01       Impact factor: 4.430

10.  FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma.

Authors:  Ana Belén Herrero; Dalia Quwaider; Luis Antonio Corchete; Maria Victoria Mateos; Ramón García-Sanz; Norma C Gutiérrez
Journal:  J Cell Mol Med       Date:  2020-03-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.